SOUTH SAN FRANCISCO, Calif.
Sept. 30, 2013
/PRNewswire/ -- KaloBios Pharmaceuticals (Nasdaq: KBIO) today announced that the company will present at the Leerink Swann Rare Disease Roundtable on
at the Le Parker Meridien in
New York City
. KaloBios President and Chief Executive Officer,
David W. Pritchard
, will provide an overview of KaloBios and the company's three current clinical programs for its proprietary, patient-targeted monoclonal antibody therapeutics.
Wednesday, October 2, 2013
10:30 AM EDT
Where: Le Parker Meridien,
New York City
To access the live and archived audio webcast of this presentation please log on through a link located in the Investors section of the KaloBios Pharmaceuticals website under the Events & Presentations tab:
A replay of the webcast will be available one hour after the conclusion of the live event.
KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat severe medical conditions with a primary clinical focus on respiratory diseases and cancer. For more information on KaloBios Pharmaceuticals, please visit our web site at
Jeffrey H. Cooper
Chief Financial Officer KaloBios Pharmaceuticals, Inc. (650) 243-3146
Joan E. Kureczka
Kureczka/Martin Associates Tel: (415) 821-2413 Mobile: (415) 690-0210
SOURCE KaloBios Pharmaceuticals